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Abstract
Background—The prognostic significance of ambulatory blood pressure (ABP) has not been
established in patients with type 2 diabetes (T2DM).
Methods—To clarify the impact of ABP on cardiovascular prognosis in patients with or without
T2DM, we performed ABP monitoring (ABPM) in 1268 subjects recruited from nine sites in
Japan, who were seen for the evaluation of hypertension. The mean age was 70.4±9.9 years, and
301 had diabetes; they were followed for 50±23 months. Incident cardiovascular disease (CVD)
were related to different measures of ABP, including three categories of awake systolic BP (SBP
<135, 135-150, and >150 mmHg), sleep SBP (<120, 120-135, and >135 mmHg), and nocturnal
BP dipping (dippers, non-dippers, and risers). Cox regression models controlling for classic risk
factors, were performed.
Results—Higher awake and sleep SBP predicted higher incidence of CVD in both diabetes and
non-diabetes groups. In multivariable analyses, elevated awake and sleep SBP predicted increased
risk of CVD more closely than clinic BP in both groups. The relationships between ABP level and
CVD were similar in both groups. In Kaplan-Meier analyses, the incidence of CVD in non-dippers
was similar to dippers, but risers experienced the highest risk of CVD in both groups (ps<0.01).
The riser pattern was associated with approximately a 150% increase in risk of CVD, in both
groups.
Conclusions—These findings suggest that ABPM improves the prediction of cardiovascular
risk, over and above clinic BP, as much in patients with type 2 diabetes as it does in patients
without diabetes.
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Type 2 diabetes is one of the most important predisposing factors for the development of
cardiovascular disease,1 particularly when associated with hypertension,2,3 and aggressive
blood pressure reduction has been shown to be very beneficial in patients with diabetes.2,4,5
Therefore, recent international guidelines for the management of hypertension recommend
that blood pressure (BP) in diabetes should be lowered to <130/80mmHg.5,6 Nevertheless,
in data from the United States National Health and Nutrition Examination Surveys
(NHANES), the percentage of diabetic patients meeting the JNC VI BP goal
(<130/85mmHg) was only 35.9 % in 2001-2002.7
There have been several studies showing that ambulatory BP (ABP) is a better predictor of
risk than traditional clinic or office BP measurement in hypertensive patients,8-12 but none
have described whether the same is true for patients with diabetes. In addition, variations in
the normal diurnal rhythm of BP such as the non-dipping or rising pattern during the
night,8-10 nocturnal hypertension,9-11 and morning hypertension13 have been reported to be
high-risk phenotypes of hypertension. Because of its limited reproducibility, some have
reported that only 65.9% of non-dippers are reproducible when ABPM was repeated without
any intervention. Again, most of the subjects in these studies were non-diabetic.8-12 ABPM
has been widely advocated for improving the estimation of cardiovascular risk in
hypertensive patients by organizations such as the American Society of Hypertension14 and
the International Society of Hypertension,15 but the American Diabetes Association has
made no recommendations on the use of out-of-office monitoring, on the grounds that there
are insufficient published data in patients with diabetes. Nevertheless, ABP, and particularly
the non-dipping pattern, has been reported to be associated more closely than clinic BP with
diabetic microvascular disease, such as nephropathy,16-21 retinopathy,22 and neuropathy,23
but the prognostic significance of ABP in type 2 diabetes has rarely been reported.24,25
There is some uncertainty as to whether the adverse prognosis associated with the non-
dipping pattern reported in mostly non-diabetic hypertensive subjects applies to non-dippers
in general, or is limited to the inverted dippers (also known as risers), as has been suggested
by the only two studies that have examined the prognosis of risers and the “true” non-
dippers (who show an absent or diminished fall of nocturnal BP, but not an increase)
separately.9,11 Therefore, the hypotheses tested in this study were that: ABP in patients with
type 2 diabetes predicts cardiovascular disease (CVD) better than clinic BP; the association
of ABP in patients with type 2 diabetes on the subsequent incidence of CVD is stronger than
in non-diabetes; and risers, but not true non-dippers, have an increased incidence of CVD
when compared with dippers.
Methods
This prospective study was performed in a sample of 1268 asymptomatic patients with
(n=301) or without (n=967) type 2 diabetes who were seen for the evaluation of
hypertension in general internal medicine clinics at 9 participating institutes in Japan: 3
clinics, 2 hospitals and one hypertension clinic of a university hospital (the Jichi Medical
School- JMS ABPM Study Wave 1); and from 1 clinic and 2 hospitals in the Karatsu-
Nishiarita Study.26-28
Subjects and definitions
During the period of recruitment, 1990-1998 for the JMS ABPM Study Wave 1 sample and
1996-2002 for the Karatsu-Nishiarita Study, hypertensive or possible hypertensive subjects
were enrolled consecutively in the clinic, and agreed to undergo ABP monitoring (ABPM).
The patients included many patients who came to the clinics first time for the evaluation of
their BP. The mean age was 70.4 ± 9.9 years (range 33-97 years); there were 483 men and
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785 women; 94 % of subjects were hypertensive. At least two clinic BP readings were taken
on each of two separate occasions after at least 5 min of rest in the sitting position, which
included before and after being fitted with an ABPM in subjects who stopped medication for
ABPM. Hypertension was diagnosed when the clinic systolic BP (SBP) was ≥140 and/or
diastolic BP (DBP) was ≥90 mmHg on at least two occasions according to current
guidelines,29 or by a previous diagnosis of hypertension with current antihypertensive
medication use. Subjects who were taking medications (N=680, 54%) stopped
antihypertensive medications for 14 days preceding the ABPM study except for certain
subjects who were not willing to stop medications long period or considered to be high risk
(e.g. family history of CVD, high clinic BP, and mild renal insufficiency). Type 2 diabetes
was diagnosed according to the guidelines of the American Diabetes Association30 or a
previous diagnosis and currently taking anti-diabetic medication. We excluded patients with
type 1 or secondary diabetes, renal dysfunction (serum creatinine >1.9 mg/dl), hepatic
damage, ischemic heart disease or other cardiac diseases, congestive heart failure,
arrhythmias (including atrial fibrillation), stroke (including transient ischemic attacks), or
other major concomitant non-cardiovascular diseases. Body mass index (BMI) was
calculated as weight (kg)/height2 (m2). Smoking was defined as current smoking. This study
was approved by the Institutional Review Board of each participating hospital or clinic. All
the subjects studied were ambulatory and gave informed consent for the study.
Ambulatory BP monitoring
Noninvasive ABPM was performed on a weekday with an automatic system (either
ABPM-630, {Nippon Colin. Co}, TM2421, or TM2425, {A&D, Tokyo}) which recorded
BP using the oscillometric method, and pulse rate every 30 minutes for 24 hours. These
devices have been previously validated.31,32 Awake and sleep time were defined based on
patients’ written diaries recorded during ABPM. Mean awake and sleep levels of SBP and
DBP were computed and the nocturnal BP fall (%) was calculated as (awake SBP–sleep
SBP)/awake SBP. Nocturnal BP fall was classified as follows: dipper if the nocturnal BP fall
was ≥10%, non-dipper if it was ≥0% but <10%, and riser if it was <0%.9,11,26 Three
categories of awake SBP level were used with cutoff values of 135 and 150 mmHg (i.e.
<135, 135-150, and >150 mmHg), and three categories of sleep SBP level with cutoff values
of 120 and 135 mmHg (i.e. <120, 120-135, and >135 mmHg). These values (awake SBP
135 mmHg and sleep SBP 120 mmHg) are recommended in multiple Hypertension
guidelines.6,29,33
Follow-up and events
The subjects’ medical records were reviewed periodically after ABPM for the purpose of
identifying incident CVD. The follow up examination of 811 participants from JMS ABPM
Study Wave 1 was performed from 1996 to 1998, and the 457 participants from the Karatsu-
Nishiarita Study from March 2004 to October 2006. The mean follow periods were 5.7 years
in the former and 9.7 years in the latter. We defined three outcomes: stroke, fatal or non-
fatal myocardial infarction (MI), and sudden cardiac death. Participants who developed a
CVD other than these three (n=27), a malignant disease (n=33), dementia or physical
inactivity (n=8), died or suffered from non-cardiovascular causes such as infection, accident,
neurologic disorders (n=13), and moved or changed their telephone number (n=4) were
censored as of the time such events took place (totally 85 subjects). The average follow-up
period was 50 ± 23 months (range: 1 to 116 months). When subjects did not visit the clinics,
we interviewed them by telephone. Strokes and cardiac events were diagnosed by the
physician caring for the patient at the time of the event, and independent neurologists or
cardiologists reviewed the cases and confirmed the diagnosis by referrals or medical records.
Stroke was diagnosed on the basis of sudden onset of a neurological deficit that persisted for
>24 hours in the absence of any other disease process that could explain the symptoms.
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Stroke events included ischemic stroke (cerebral infarction and cerebral embolism),
hemorrhagic stroke (cerebral hemorrhage and subarachnoid hemorrhage), and undefined
types of stroke. We excluded transient ischemic attacks (n=4), in which the neurological
deficit cleared completely in <24 hours.11 MI was diagnosed based on the AHA criterion of
“definite” MI.34 Angina (n=8), congestive heart failure (n=9), end stage renal disease (n=2),
peripheral artery disease (n=3), and arrhythmia needing permanent pacemaker (n=1) were
not treated as endpoints.
Statistical analyses
All statistical analyses were carried out with SPSS/Windows, version 13.0 (SPSS Inc.,
Chicago, Illinois). The data are expressed as the mean (± SD) or percentage. The chi-square
test was used to compare proportions. The independent samples t test was performed to test
mean differences between groups. The log-rank statistic was used to test the differences
among Kaplan-Meier survival curves. Adjusted hazard ratios (HRs) with 95% confidence
intervals were based on multivariable Cox regression analysis. As a preliminary analysis, we
performed Cox regression analysis using variables except for BP parameters: age, sex, BMI,
smoking status, creatinine, cholesterol, triglycerides, and the use of antihypertensive
medication. As a result, age, smoking, and creatinine survived, then we determined to use
essential variables (age, sex, and BMI) and smoking status, and creatinine as non-BP
variables. Analyses were initially performed separately for diabetes and non-diabetes
groups. In order to test for group differences in the relationship of ABP to incident CVD,
interaction terms (between the measures of ABP and the presence of diabetes) were tested in
the full sample. The null hypothesis was rejected when two-tailed P<0.05.
Results
The BMI, 24-hour BP, and awake BP were similar in the diabetes and non-diabetes groups
(Table1). There were, however, some differences: the percentage of males, current smoking,
hematocrit, triglycerides, sleep SBP, 24-hour and sleep pulse rates, and the proportion of
true non-dippers and risers were significantly higher in patients with diabetes than in non-
diabetes. The age, serum creatinine, and clinic BP were significantly higher in patients with
non-diabetes than in diabetes.
During the follow-up of 50 ± 23 months, 100 cardiovascular events occurred. The incidence
of CVD was 2.1/100 person-years in diabetes and 1.8/100 person-years in non-diabetes. The
actual numbers of event (%) are listed in Table 2. As shown, the Risers had the highest event
rates followed by non-dippers and dippers in both diabetics and non-diabetics. In univariate
analyses, clinic SBP was significantly associated with CVD in both diabetes and non-
diabetes, but the measures of ambulatory BP had better predictions (Table 3, A and B). In
multivariable Cox regression analyses that controlled for age, sex, BMI, antihypertensive
drugs, serum creatinine, and site, clinic SBP was independently associated with CVD in
both diabetes and non-diabetes groups (Model 1, Table 3). However, when 24-hour SBP,
awake SBP, sleep SBP, or both awake and sleep SBPs were entered into the models (Models
2 thru 5), clinic SBP was no longer a significant predictor of CVD. In Model 2, 24-hour SBP
was independently associated with CVD in both diabetes (P<0.001) and non-diabetes
(P=0.001) groups. When awake and sleep SBP were entered one by one in the same models
(Models 3 and 4), they were independently associated with CVD in both diabetes and non-
diabetes groups. Finally, when awake and sleep SBP were entered together (Model 5),
awake SBP in diabetes and sleep SBP in non-diabetes were most closely associated with
CVD, although neither was significantly better than the other measure.
The Kaplan-Meier survival curves for the three categories of awake SBP (awake SBP<135-
lowest, 135-150-middle, and >150 mmHg-highest) and sleep SBP (sleep SBP<120-lowest,
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120-135-middle, and >135 mmHg-highest) are shown in Figure 1. The number of events in
those awake and sleep SBP groups are shown in Table 4. In diabetes group, the highest and
middle categories had a significantly higher incidence of CVD than the lowest category.
However, the difference between the highest and the middle category was not statistically
significant. In non-diabetes, the highest category had a higher incidence of CVD than the
other two, but the difference between the middle and the lowest category was not
significant. The highest sleep SBP category had a higher incidence of CVD than the others
in both diabetes and non-diabetes groups. However, the difference was not significant
between the middle and the lowest categories in either group, nor between the highest and
the middle categories in non-diabetics.
In order to determine if the difference between diabetes and non-diabetes groups, we
performed an additional multivariable analysis in the whole population to clarify the
interactions between the measures of ABP and the presence of diabetes. However, none of
the interactions between diabetes and the ABP measures (24-hour, awake, and sleep SBP,
and non-dipper and risers) were statistically significant.
In Model 6 of Table 3, the non-dipping pattern (defined as riser plus true non-dipper) was
not associated with increased risk of CVD in either diabetes or non-diabetes groups. In
contrast, the riser pattern was a stronger independent predictor for CVD than the dipper and
true non-dipper patterns in both groups (Model 7, Table 3) although the result was not
statistically significant in diabetes group.
Discussion
It is established that ABP predicts CVD better than clinic BP in essential hypertensive
patients,8,10,12 but the clinical significance of ABP as a predictor for CVD in diabetes has
not yet been established.35 In the present study, which is the first to compare the prediction
of cardiovascular events by ABPM and clinic BP in patients with diabetes and non-diabetics
from the same cohort, we showed that 24-hour BP was independently associated with future
cardiovascular events in both groups. There have been a few studies in diabetes showing
associations of ABP with cardiovascular outcomes36 and all-cause mortality,25,37 but they
had significant limitations: in one case ABPM was performed in a hospital setting 36; in
another the study design was retrospective and the number of patients was small 25; and in
the third only clinic and ambulatory PP were used in the analysis, and the contributions of
ambulatory awake/sleep PPs or ambulatory SBP/DBP were not analyzed.37 As a result, the
utility of ABPM in patients with diabetes is not yet accepted. In our study, although clinic
SBP predicted cardiovascular risk, it was no longer significant in either group after 24-hour
BP had been entered. Although the second hypothesis that the prediction of ABPM in
diabetes is better than non-diabetes was not supported in our data, we could see the trends.
These findings documenting the importance of ABPM for predicting CVD in patients with
diabetes compared with non-diabetes in the same study have not been reported before.
ABPM can assess the “true” or “mean” BP levels, and also the diurnal rhythm of BP.3839
The importance of BP control in patients with diabetes has been shown in many outcome
trials,2,4 and review articles,3,40 but the BP has so far been evaluated only by clinic BP.
Despite this lack of evidence, the International Diabetes Federation has recommended using
ABPM and home BP monitoring as diagnostic tools for evaluation of BP.41
In patients with diabetes, it has been reported that sleep BP was better associated with target
organ damage16,18,22,23 or incident vascular events24 than awake BP. In contrast, in our
data, awake BP had a similar prediction of incident CVD to sleep BP. This result is partly in
agreement with a paper showing that the awake BP was a significant marker of albuminuria
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in elderly subjects with diabetes.21 The exact reason for this finding is unknown, but it is
possible that some diabetes-specific factors may be operating. Because ABPM in our
subjects was performed in patients’ natural daily-life settings, the amount of physical
activity was not restricted. Hypertensive patients with diabetes generally have more severe
target organ damage than those without diabetes,28 and BP regulation may be impaired by
autonomic neuropathy.42 Therefore BP increases occurring during daily life stress might
trigger CVD events.
In most previous studies, the category of “non-dipping” combines those whose BP declines
little during the night (the true non-dippers as defined in this study) and those whose BP
actually rises (the risers). It has been reported that a blunted nocturnal BP fall is associated
with CVD in hypertensive patients,8-12 and in diabetes it has been reported to be associated
with diabetic microvascular complications such as nephropathy,16,18 retinopathy22 and
autonomic neuropathy,23 which suggests that the non-dipping pattern should be associated
with a higher incidence of CVD in patients with type 2 diabetes. Such a positive association
between non-dipping and CVD in diabetes has been reported in one Japanese study,36 but
the ABPM was performed in hospital. Furthermore, the daytime BP value may have been
artificially low43 because the extent of physical activity is limited in the hospital setting,
which probably led to some dippers being misclassified as non-dippers. There has been
another study showing an association between non-dipping and all cause mortality in
diabetes,25 but the sample size was too small to provide a definite conclusion. Therefore,
these previous reports are inconclusive, and our report is the first to describe the relationship
between the dipping pattern evaluated by out-of-hospital ABPM and cardiovascular
prognosis in type 2 diabetics; we found that the event rate of non-dippers was not different
from dippers. The classification of non-dipping is recognized as being generally not very
reproducible,44 but this may not be the case in diabetics.45
Riser, or reverse pattern has been reported in patients with severe autonomic dysfunction
and closely associated with adverse CV events. Only two previous studies have attempted to
distinguish risers from true non-dippers, but both concluded that the increased risk
associated with non-dipping is largely attributable to the risers, both for cardiovascular
mortality9 and stroke events.11 And in one analysis using a continuous variable of the night-
day ratio of SBP, the event rate was highest in the risers.10 As shown in Model 6 (Table 3),
when risers and non-dippers are combined, the increase in risk associated with the non-
dipping pattern is small and non-significant in both diabetes and non-diabetes; when the
risers are differentiated from the non-dippers (Model 7), the risers experience approximately
a 150% greater risk than the normal dippers, while the true non-dippers exhibit only a small
increase in risk that does not approach statistical significance. This finding has at least two
possible implications: first, it may explain the apparent paradox of why we did not confirm
that the non-dipping pattern predicts risk in diabetics, and second, that other studies should
pay greater attention to the distinction between true non-dippers and risers.
This study has some limitations. Our data were derived from an elderly and predominantly
female population, and the BMI was lower than in western populations.1,2 Because the focus
in this study was the predictive utility of ABPM for hypertensive patients with diabetes, and
diabetes and non-diabetes groups were from the same cohort, we believe that these
differences in population characteristics are not a problem. Because of the limited number of
risers in the diabetes group, the risk prediction of ABP in diabetes was statistically not more
predictive than that in non-diabetes and the riser pattern (Model 7, Table 2) was not
statistically significant, although the HR was similar to that seen in non-diabetes group.
Further study is needed to resolve this issue.
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In conclusion, the ambulatory BP level, especially awake BP, was a strong predictor for
cardiovascular events in patients with type 2 diabetes. The findings suggest that this may be
different from the pattern seen in non-diabetes, where sleep BP appears to be more closely
associated with cardiovascular events than awake BP. The risers, but not non-dippers, were
at increased risk of cardiovascular events in both the diabetes and non-diabetes groups. Our
findings provide strong support for the use of ABPM in the management of hypertensive
patients with type 2 diabetes, and the fact that the awake BP was an equally important
predictor to sleep BP raises the possibility that home BP monitoring might also have
prognostic utility.
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Event-free survival Kaplan-Meier curves for three categories of awake and sleep SBP. The
numbers of subjects and events in each category are shown in the Table 4. Log-rank statistic
between highest- vs. lowest-awake SBP is 11.2 (P=0.001) for diabetes and 8.4 (P=0.004) for
non-diabetes groups, that of middle- vs. lowest-awake SBP is 4.5 (P=0.03) for diabetes and
1.0 (P=0.32) for non-diabetes groups. Log-rank statistic between highest- vs. middle- awake
SBP is 1.8 (P=0.19) for diabetes and 4.0 (P=0.046) for non-diabetes groups. Log-rank
statistic between highest- vs. lowest-sleep SBP is 16.3 (P<0.001) for diabetes and 11.3
(P=0.001) for non-diabetes, that of middle- vs. lowest-sleep SBP is 3.3 (P=0.07) for diabetes
and 3.8 (P=0.05) for non-diabetes groups. Log-rank statistic between highest- vs. lowest-
sleep SBP is 6.4 (P=0.01) for diabetes and 1.9 (P=0.17) for non-diabetes. SBP indicates
systolic blood pressure.
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Table 1 (a)







Age (years) 71.3 ± 10.7 67.8 ± 9.6 67.2 ± 9.3 0.12
Male sex (%) 44 52 46 0.61
Body mass index (kg/m2) 22.6 ± 3.3 24.6 ± 4.1 24.1 ± 3.2 0.04
Smoker (%) 37 30 35 0.57
Antihypertensive medication (%) 70 51 60 0.11
Hematocrit (%) 37.4 ± 8.3 41.1 ± 4.0 40.6 ± 4.4 0.001
Triglycerides (mg/dl) 140 ± 66 147 ± 102 140 ± 86 0.83
Serum creatinine (mg/dl) 0.77 ± 0.24 0.81 ± 0.22 0.78 ± 0.26 0.48
Cockcroft -Gault GFR (ml/min) 68 ± 28 74 ± 30 76 ± 31 0.41
Clinic SBP (mmHg) 162 ± 26 151 ± 23 154 ± 20 0.054
Clinic DBP (mmHg) 85 ± 15 82 ± 14 85 ± 14 0.25
24-hour SBP (mmHg) 151 ± 19 140 ± 19 139 ± 15 0.003
24-hour DBP (mmHg) 83 ± 9 79 ± 11 79 ± 8 0.08
Awake SBP (mmHg) 147 ± 18 143 ± 20 148 ± 17 0.07
Awake DBP (mmHg) 83 ± 9 80 ± 11 84 ± 9 0.03
Sleep SBP (mmHg) 158 ± 20 134 ± 20 123 ± 14 <0.001
Sleep DBP (mmHg) 83 ± 11 76 ± 11 70 ± 8 <0.001
24-hour PR (beats/min) 71 ± 9 70 ± 8 72 ± 9 0.20
Awake PR (beats/min) 75 ± 10 73 ± 9 76 ± 10 0.07
Sleep PR (beats/min) 64 ± 9 63 ± 9 62 ± 9 0.66
White-coat hypertension (%) 22.2 16.1 12.2 0.33
Calcium channel blockers (%) 44 31 37 0.39
ARB (%) 0 6 5 0.44
ACE inhibitors (%) 33 25 24 0.62
Diuretics (%) 7 7 3 0.20
β-blockers (%) 0 3 7 0.11
α-blockers (%) 7 2 3 0.25
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Table 1 (b)







Age (years) 75.2 ± 9.6 72.0 ± 9.8 70.2 ± 9.9 <0.001
Male sex (%) 48 37 32 0.02
Body mass index (kg/m2) 22.6 ± 3.4 23.4 ± 3.7 24.2 ± 3.3 <0.001
Smoker (%) 25 24 15 0.001
Antihypertensive medication (%) 49 52 53 0.86
Hematocrit (%) 39.6 ± 8.2 39.1 ± 4.5 39.8 ± 4.4 0.15
Triglycerides (mg/dl) 124 ± 61 132 ± 67 135 ± 70 0.38
Serum creatinine (mg/dl) 0.89 ± 0.19 0.88 ± 0.20 0.86 ± 0.23 0.32
Cockcroft -Gault GFR (ml/min) 52 ± 19 56 ± 19 61 ± 21 <0.001
Clinic SBP (mmHg) 167 ± 19 162 ± 17 163 ± 18 0.06
Clinic DBP (mmHg) 86 ± 17 89 ± 13 91 ± 13 0.009
24-hour SBP (mmHg) 142 ± 19 140 ± 16 137 ± 16 0.002
24-hour DBP (mmHg) 79 ± 10 79 ± 10 78 ± 10 0.39
Awake SBP (mmHg) 139 ± 19 143 ± 17 147 ± 17 <0.001
Awake DBP (mmHg) 78 ± 11 80 ± 10 83 ± 11 <0.001
Sleep SBP (mmHg) 145 ± 19 135 ± 16 120 ± 15 <0.001
Sleep DBP (mmHg) 80 ± 12 76 ± 10 69 ± 10 <0.001
24-hour PR (beats/min) 69 ± 7 69 ± 8 70 ± 7 0.45
Awake PR (beats/min) 73 ± 8 74 ± 9 76 ± 9 0.004
Sleep PR (beats/min) 60 ± 7 60 ± 8 60 ± 8 0.93
White-coat hypertension (%) 38.0 26.9 19.5 <0.001
Calcium channel blockers (%) 31 33 39 0.20
ARB (%) 0 3 2 0.29
ACE inhibitors (%) 18 19 17 0.89
Diuretics (%) 8 4 5 0.28
β-blockers (%) 0 2 2 0.50
α-blockers (%) 0 1 1 0.79
Data are shown as percentage or mean ± SD.
SBP, systolic blood pressure; DBP, diastolic blood pressure; PR, pulse rates;
ARB, Angiotensin II receptor blockers; ACE, angiotensin-converting enzyme
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Table 2
Number of events in each dipping group
Dippers Non-dippers Risers P value
Diabetes 11/156 (7.1%) 11/118 (9.3%) 7/27 (25.9%) 0.012
Non-diabetes 34/591 (5.8%) 24/305 (7.9%) 13/71 (18.3%) 0.001
 Overall 45/747 35/423 20/98 <0.001
Data are shown as number (%).
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Table 3
Multivariable Cox regression analysis predicting incident cardiovascular events
A. Diabetes









































Riser vs. dipper 2.55(0.88-7.33)
−2log likelihood 270.5 261.4 261.4 262.3 260.1 268.0 267.4
  χ 2 - 9.1 9.1 8.2 10.4 2.5 3.1
P value - 0.003 0.003 0.004 0.006 0.11 0.08
B. Non-diabetes









































Riser vs. dipper 2.39
*
(1.23-4.65)
−2log likelihood 845.0 835.7 840.0 839.3 838.4 843.9 838.8
  χ 2 - 9.3 5.0 5.7 6.6 1.1 6.2
P value - 0.002 0.03 0.02 0.04 0.29 0.01







SBP indicates systolic blood pressure.
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†Non-dipping includes true non-dippers and risers. Each model was adjusted for age, sex, BMI, smoking, and serum creatinine. Comparison of log-
likelihood functions, based on chi-square distribution are shown as −2 log likelihood and χ2 in the bottom of each model. The −2 log likelihood
and χ2 indicate improvement vs. Model 1 for clinic SBP. The p-values indicate for the improvements in the model when awake and/or sleep
ambulatory BP are added to the equations, which were highly significant, and their significance levels were essentially the same as those of the
regression estimate for the ABP measure.
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Table 4
Number of events in each SBP group stratified by awake and sleep SBP
Awake SBP<135 Awake SBP 135-150 Awake SBP >150 P value
Diabetes 2/91 (2.2%) 11/108 (10.2%) 16/102 (15.7%) 0.002
Non-diabetes 16/274 (5.8%) 19/335 (5.7%) 36/358 (10.1%) 0.03
Overall 17/365 30/443 52/460
Sleep SBP≤120 Sleep SBP 120-135 Sleep SBP >135 P value
Diabetes 2/100 (2.0%) 7/93 (7.5%) 20/108 (18.5%) <0.001
Non-diabetes 16/365 (4.4%) 23/305 (7.5%) 32/297 (10.8%) 0.002
Overall 18/465 30/398 52/405
Data are shown as number (%).
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